Mukherjee Rajarshi, Nunes Quentin, Huang Wei, Sutton Robert
Liverpool Pancreatitis Research Group, Royal Liverpool University Hospital and Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Precis Clin Med. 2019 Jun;2(2):81-86. doi: 10.1093/pcmedi/pbz010. Epub 2019 Jun 21.
Acute pancreatitis is a common inflammatory condition affecting the pancreas, predominantly caused by gallstones, alcohol excess, and hypertriglyceridaemia, with severe disease carrying up to 50% mortality. Despite significant research and preclinical promise, no targeted drug treatments exist for the disease and precision medicine approaches are lacking significantly, when compared to other health conditions. Advances in omics applications will facilitate improved preclinical models and target identification as well as biomarker discovery for refined trial design, focusing on risk stratification, subject selection, and outcome determination. Randomised treatment of Acute Pancreatitis with Infliximab: Double-blind, placebo-controlled, multi-centre trial (RAPID-I) is a pioneering trial, currently under way in acute pancreatitis, which may serve as an innovative model for the implementation of precision medicine strategies for acute pancreatitis in the future.
急性胰腺炎是一种常见的影响胰腺的炎症性疾病，主要由胆结石、酗酒和高甘油三酯血症引起，重症患者的死亡率高达50%。尽管进行了大量研究且临床前研究前景良好，但与其他健康状况相比，该疾病尚无靶向药物治疗，且精准医学方法严重匮乏。组学应用的进展将有助于改进临床前模型、靶点识别以及生物标志物发现，以优化试验设计，重点关注风险分层、受试者选择和结果判定。英夫利昔单抗随机治疗急性胰腺炎：双盲、安慰剂对照、多中心试验（RAPID-I）是一项开创性试验，目前正在急性胰腺炎领域进行，它可能成为未来实施急性胰腺炎精准医学策略的创新模型。
